329 related articles for article (PubMed ID: 7812911)
21. Proliferative characteristics of intestinalized mucosa in the distal esophagus and gastroesophageal junction (short-segment Barrett's esophagus): a case control study.
Gulizia JM; Wang H; Antonioli D; Spechler SJ; Zeroogian J; Goyal R; Shahsafaei A; Chen YY; Odze RD
Hum Pathol; 1999 Apr; 30(4):412-8. PubMed ID: 10208462
[TBL] [Abstract][Full Text] [Related]
22. Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.
Kazeminezhad B; Mirafsharieh SA; Dinyari K; Azizi D; Ebrahimi A
Turk J Gastroenterol; 2014 Jun; 25(3):253-6. PubMed ID: 25141312
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of Barrett's esophagus with CK7, CK20, p53, Ki67, and COX2 expressions using chromoendoscopical examination.
Çoban Ş; Örmeci N; Savaş B; Ekiz F; Ensari A; Kuzu I; Palabıyıkoğlu M
Dis Esophagus; 2013; 26(2):189-96. PubMed ID: 22591041
[TBL] [Abstract][Full Text] [Related]
24. Zoning of mucosal phenotype, dysplasia, and telomerase activity measured by telomerase repeat assay protocol in Barrett's esophagus.
Going JJ; Fletcher-Monaghan AJ; Neilson L; Wisman BA; van der Zee A; Stuart RC; Keith WN
Neoplasia; 2004; 6(1):85-92. PubMed ID: 15068673
[TBL] [Abstract][Full Text] [Related]
25. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma.
Singh SP; Lipman J; Goldman H; Ellis FH; Aizenman L; Cangi MG; Signoretti S; Chiaur DS; Pagano M; Loda M
Cancer Res; 1998 Apr; 58(8):1730-5. PubMed ID: 9563491
[TBL] [Abstract][Full Text] [Related]
26. Molecular evaluation of ablative therapy of Barrett's oesophagus.
Hage M; Siersema PD; Vissers KJ; Steyerberg EW; Haringsma J; Kuipers EJ; van Dekken H
J Pathol; 2005 Jan; 205(1):57-64. PubMed ID: 15586364
[TBL] [Abstract][Full Text] [Related]
27. A cross sectional study of p504s, CD133, and Twist expression in the esophageal metaplasia dysplasia adenocarcinoma sequence.
Ahmad J; Arthur K; Maxwell P; Kennedy A; Johnston BT; Murray L; McManus DT
Dis Esophagus; 2015 Apr; 28(3):276-82. PubMed ID: 24612412
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry.
Ramel S; Reid BJ; Sanchez CA; Blount PL; Levine DS; Neshat K; Haggitt RC; Dean PJ; Thor K; Rabinovitch PS
Gastroenterology; 1992 Apr; 102(4 Pt 1):1220-8. PubMed ID: 1551529
[TBL] [Abstract][Full Text] [Related]
29. Cyclooxygenase-2 expression in esophageal epithelium before and after photodynamic therapy for Barrett's esophagus with high-grade dysplasia or intramucosal carcinoma.
Yachimski P; Mino-Kenudson M; Sherwood ME; Puricelli WP; Nishioka NS; Lauwers GY
Virchows Arch; 2011 Dec; 459(6):581-6. PubMed ID: 22081106
[TBL] [Abstract][Full Text] [Related]
30. The diagnosis and management of Barrett's esophagus.
DeMeester SR; DeMeester TR
Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
[TBL] [Abstract][Full Text] [Related]
31. Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett's esophagus cohort.
Lomo LC; Blount PL; Sanchez CA; Li X; Galipeau PC; Cowan DS; Ayub K; Rabinovitch PS; Reid BJ; Odze RD
Am J Surg Pathol; 2006 Apr; 30(4):423-35. PubMed ID: 16625087
[TBL] [Abstract][Full Text] [Related]
32. Increased p53 expression in the malignant transformation of Barrett's esophagus is accompanied by an upward shift of the proliferative compartment.
Hritz I; Gyorffy H; Molnar B; Lakatos G; Sipos F; Pregun I; Juhasz M; Pronai L; Schaff Z; Tulassay Z; Herszenyi L
Pathol Oncol Res; 2009 Jun; 15(2):183-92. PubMed ID: 18752044
[TBL] [Abstract][Full Text] [Related]
33. Downregulation of TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L in Barrett's esophagus with dysplasia and adenocarcinoma.
Popnikolov NK; Gatalica Z; Adegboyega PA; Norris BA; Pasricha PJ
Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):161-5. PubMed ID: 16785783
[TBL] [Abstract][Full Text] [Related]
34. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
35. Increased immunoreactivity for Rab11, a small GTP-binding protein, in low-grade dysplastic Barrett's epithelia.
Ray GS; Lee JR; Nwokeji K; Mills LR; Goldenring JR
Lab Invest; 1997 Nov; 77(5):503-11. PubMed ID: 9389793
[TBL] [Abstract][Full Text] [Related]
36. Apoptotic and proliferative activity in the neoplastic progression of Barrett's oesophagus: a comparative study.
Whittles CE; Biddlestone LR; Burton A; Barr H; Jankowski JA; Warner PJ; Shepherd NA
J Pathol; 1999 Apr; 187(5):535-40. PubMed ID: 10398118
[TBL] [Abstract][Full Text] [Related]
37. Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
Griffiths EA; Pritchard SA; McGrath SM; Valentine HR; Price PM; Welch IM; West CM
Br J Cancer; 2007 May; 96(9):1377-83. PubMed ID: 17437013
[TBL] [Abstract][Full Text] [Related]
38. Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus.
Glickman JN; Blount PL; Sanchez CA; Cowan DS; Wongsurawat VJ; Reid BJ; Odze RD
Hum Pathol; 2006 Oct; 37(10):1304-15. PubMed ID: 16949933
[TBL] [Abstract][Full Text] [Related]
39. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
40. Cellular kinetics in Barrett's epithelium carcinogenic sequence: roles of apoptosis, bcl-2 protein, and cellular proliferation.
Lauwers GY; Kandemir O; Kubilis PS; Scott GV
Mod Pathol; 1997 Dec; 10(12):1201-8. PubMed ID: 9436964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
